Company proved once again the success of its current business model based on generating revenue through leveraging its technology and expertise in antibody generation
Haptogen reports that it has triumphed once again at a major conference for the life sciences sector.
Representatives from biotech companies from across the UK took part in an event at the BIA Thistle Bioscience Forum 2007 where each had 15 minutes to 'showcase' their business to a panel of UK expert investors and advisers.
It was the confident pitch delivered by Andy Porter, co-founder and CTO of Haptogen, on the continued development of the company's corporate strategy that secured the top Rising Star award.
Porter described the strategic development of the company, which has a focus on groundbreaking research into new treatments for inflammation and infectious diseases.
He outlined how Haptogen was now focusing on the development of its research into a strong therapeutic antibody pipeline which would see products being tested in the clinic from 2009.
Haptogen proved once again the success of its current business model based on generating revenue through leveraging its technology and expertise in antibody generation.
This recognition by an independent panel of experts supports the approach which continues to deliver strong revenue growth and industry interest.
This latter point was demonstrated by the conclusion of five major collaborative deals with established international companies in the last 2 months.
Jim Reid, CEO of Haptogen said: "This prize gives recognition to our courageous decision to continue to progress from a technology and service driven company to a company committed to developing novel medicines for the treatment of diseases which affected hundreds of millions of people worldwide.
"We are currently discussing various financial options to fast-track these exciting developments".
Professor Porter and Jim Reid won the title Ernst and Young UK entrepreneur of the year in the science and technology ca9tegory in 2005.
In November that year Haptogen was named as a 'Rising Star' in Deloitte's technology awards.
Furthermore, last February the Herald newspaper included Haptogen in its list of top ten new Scottish businesses.
